SC 13D Filing

Company

Summit Therapeutics Inc.

Filed

January 23, 2020

Accession Number

0000921895-20-000159

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →